VEGFA and hepatocellular carcinoma: There is a good rationale for combining VEGF/PD-(L)1 blockade in HCC, given the pre-existing evidence of anti-angiogenic efficacy in HCC and the role of VEGF(R) in maintaining an immunosuppressive TME.